

Attorney Docket No. STK-081 (7557/65)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Chubinskaya et al.

SERIAL NO.:

10/081,163

GROUP NO.:

1641

FILING DATE:

February 20, 2002

EXAMINER:

Not yet assign

TITLE:

YCENIER 1600/200 Methods of Using Bone Morphogenic Proteins as Biomarkers for

Determining Cartilage Degeneration and Aging

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any documents referred to as enclosed herein, are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Commissioner for Patents, Washington, DC 20231, on this 26th day of February, 2003.

Date

Commissioner for Patents Washington, D.C. 20231

Sir:

Submitted herewith is/are:

Transmittal Form (1 pg.); Second Supplemental Information Disclosure Statement (2 pgs.); PTO-1449 (1 pg.); Cited Art A6-A7, B15-B16 and C77-C78; this Certificate of First Class Mailing and return receipt postcard.

2585961

TP	E									
J.	() () () () () () () () () ()		Application	Serial Number	10/0	10/081,163				
0 1	[2003 E)	Filing Date	Filing Date First Named Inventor Group Art Unit		February 20, 2002 Chubinskaya 1641 Not yet assigned Chubinskaya					
VAK .		First Named								
Vr	TANSMITTA	Group Art U								
G IR		Examiner Name		Not						
	FORM	Attorney Do	cket No.	STK	STK-081 Not applicable					
		Patent No.		Not						
			Issue Date		Not	Not applicable				
,		EN	ICL OCUPES (-	harball that apply						
Fe	e Transmittal Form	EN	Copy of Notice	to File Missing eation (PTO-1553)		Notice of Appeal to Board of Patent Appeals and Interferences				
	☐ Check Attached☐ Copy of Fee Transmittal Form		Formal Drawin			Appeal Brief (in triplicate)				
_	Amendment/Response		Request For Control (Inc.) Examination (Inc.) Transmittal			Status Inquiry				
	After Final	_			\boxtimes	Return Receipt Postcard				
	Affidavits/declaration(s) Letter to Official Draftsperson	Power of Att (Revocation		ney Prior Powers)	⊠	Certificate of First Class Mailing under 37 C.F.R. 1.8				
	including Drawings [Total Sheets]		Terminal Disc	laimer		Certificate of Facsimile Transmission under 37 C.F.R. 1.8				
	Petition for Extension of Time			aration and Power r Utility or Design tion		Additional Enclosure(s) (please identify below)				
\boxtimes	Second Supplemental Information Disclosure Statement		Small Entity S	tatement						
1.	Form PTO-1449 Copies of IDS Citations		CD(s) for large	e table or computer						
	Certified Copy of Priority		Amendment A	fter Allowance						
	Document(s) Sequence Listing submission Paper Copy/CD Computer Readable Copy Statement verifying identity of above		Correction	☐ Certificate of Correction (in		·				
CORR	ESPONDENCE ADDRESS			SIGNATURE BI	оск	D				
Direct :	all correspondence to: Patent Ad Testa, Hu High Stre 125 High Boston, N Tel. No.: Fax No.:	Thibeault, LLP 0 3-7000	Date: February 26, Reg. No. 43,153 Tel. No.: (617) 316 Fax No.: (617) 248	Diana M. Steel Attorney for Applicants Testa, Hurwitz & Thibeault, LLP High Street Tower 125 High Street Boston, MA 02110						



PATENT Attorney Docket No. STK-081 (7557/65)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Chubinskaya et al.

SERIAL NO.:

10/081,163

GROUP NO.:

1641

FILING DATE:

February 20, 2002

EXAMINER:

Not yet assigned

TITLE:

TECH CENTER 1800/200 Methods of Using Bone Morphogenic Proteins as Biomarkers for

Determining Cartilage Degeneration and Aging

Commissioner for Patents Washington, D.C. 20231

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

7

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

(1)	continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or
(2)	after the period defined in (1) but before the mailing date of a final action or a notice of allowance under 37 C.F.R. 1.311, and
	the requisite Statement is below, OR
	the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein, or

Second Supplemental Information Disclosure Statement Serial No. 10/081,163 Page 2 of 2

	(3)	after the mailing date of a final action or notice of allowance but before the payment of the issue fee, AND
		the requisite Statement is below, AND
		the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein.
It is re	espectf	ully requested that each of the patents and publications listed on the attached Form
PTO-1449,	and of	her information contained herein, be made of record in this application.
		STATEMENT
As re	quired	under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that:
	1.	Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
	2.	No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Date: February 26, 2003

Reg. No. 43,153

Tel. No.: (617) 310-8168 Fax No.: (617) 248-7100 Diana M. Steel

Attorney for Applicants

Testa, Hurwitz, & Thibeault, LLP

High Street Tower 125 High Street

Boston, Massachusetts 02110

2585952



FORM PTO - 1449

ATTORNEY DOCKET NO.: STK-081

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

APPLICANTS: Chubinskaya et al.

DISCLUSURE STATEMENT					SERIAL NO.: 10/081,163 FILING DATE: February 20, 2002 GROUP: 1645						
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME			CLASS	SUB CLASS	ı	FILING DATE IF APPROPRIATE	
	A6	5,707,810	01/13/98	Smart et a	nart et al.			6			
	A7	6,194,376 B1	02/27/01	Kuberasar	mpath et al.		514	2			
			FORE	EIGN PATE	NT DOC	JMENTS	<u> </u>				
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS SUB FILING ABSTR CLASS DATE ONLY		ABSTR/ ONLY	ACT	ENGLISH LANG Y/N		
	B15"	96/39431	12/12/96	wo						Y	
	B16	98/54572	12/03/98	wo						Y	
			OTHER A	ART, JOURI	NAL ART	ICLES, I	ETC.	•		 	
EXAM. INIT.	ОТН	IER DOCUME	NTS: (Includi	ng Author, Ti	tle, Date, R	elevant Pa	ges, Place o	f Publicat	ion)		
5	To C77 International Search Report for International Patent Application No. PCT/US02/05551, date February 18, 2003, 10 pages.								551, dated		
·	Bauer et al., (1999), "Biochemical Markers of Bone Turnover and Prediction of Hip Bone Lo in Older Women: The Study of Osteoporotic Fractures", J. Bone Mineral Res., 14:1404-1410										
EXAMINER					DATE CONSIDERED						

2585953

